Extended Data Fig. 3. ctDNA trends for patients with discordant molecular and radiographic RECIST responses.

(a) For patient BR360019, clearance of KRAS G12C at C2D1 signified ctDNA molecular response, which was discordant with the RECIST radiographic assessment of disease progression. (b) In contrast, patient BR360041 showed persistence of NRAS Q61L at C3D1 and was as such classified in the molecular disease progression category that while discrepant with a RECIST assessment of partial response, more accurately reflected a short progression-free survival of 1.47 months. (c) Notably, for patient BR360017 that had radiographically stable disease, clearance of KRAS G12V at C2D1 signified ctDNA molecular response and accurately captured the patient’s ongoing progression-free and overall survival of >13 months.